Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: SLE (Systemic Lupus) Clear all
Completed Phase 2 Interventional Results available

ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

NCT04835441
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
ALPN-101, Placebo
Drug
Lead sponsor
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Anniston, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jul 22, 2026, 11:18 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

NCT05966480
View directory record Official record
Conditions
SLE
Interventions
Envudeucitinib, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
48
States / cities
Anniston, Alabama • La Jolla, California • Los Alamitos, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 11:18 PM EDT
Recruiting Phase 1 Interventional

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

NCT07011043
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Budoprutug
Drug
Lead sponsor
Climb Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Allen, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 22, 2026, 11:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Duke Autoimmunity in Pregnancy Registry

NCT00513591
View directory record Official record
Conditions
Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Jul 22, 2026, 11:18 PM EDT
Completed Phase 1Phase 2 Interventional

Anti-CD20 in Systemic Lupus Erythematosus

NCT00036491
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
3
States / cities
Denver, Colorado • Rochester, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 22, 2026, 11:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

NCT03393013
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
KZR-616
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
17
States / cities
Los Angeles, California • Upland, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jul 22, 2026, 11:18 PM EDT
Completed Phase 1 Interventional

MSC2364447C Phase 1b in Systemic Lupus Erythematosus

NCT02537028
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
MSC2364447C, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Anniston, Alabama • El Cajon, California • Lakewood, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced Jul 22, 2026, 11:18 PM EDT
Not listed Phase 1 Interventional

Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)

NCT03878303
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
AC0058TA, Placebo AC0058TA
Drug
Lead sponsor
ACEA Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Jul 22, 2026, 11:18 PM EDT
Completed Phase 1Phase 2 Interventional

Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)

NCT00094380
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions
CTLA4-IgG4m (RG2077), Cyclophosphamide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jul 22, 2026, 11:18 PM EDT
Completed Phase 2 Interventional Results available

Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches

NCT02270957
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Jul 22, 2026, 11:18 PM EDT
Recruiting No phase listed Observational

Research Accelerated by You Lupus Registry

NCT06927219
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Cutaneous Lupus Erythematosus (CLE)
Interventions
Not listed
Lead sponsor
Lupus Foundation of America
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 22, 2026, 11:18 PM EDT
Recruiting No phase listed Observational

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

NCT04751396
View directory record Official record
Conditions
Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis, Enteropathic Spondylitis, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis
Interventions
Best Practice, Educational Intervention, Interview, Questionnaire Administration, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 22, 2026, 11:18 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

NCT05856448
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
GLPG3667, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years to 75 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
22
States / cities
Tucson, Arizona • La Jolla, California • Rancho Mirage, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 22, 2026, 11:18 PM EDT
Completed Phase 2 Interventional Results available

A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

NCT02962960
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Thousand Oaks, California • Orlando, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jul 22, 2026, 11:18 PM EDT
Recruiting Phase 3 Interventional

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

NCT07355218
View directory record Official record
Conditions
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Interventions
Enpatoran, Placebo, Standard of care (SoC)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Upland, California • DeBary, Florida • Hollywood, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 11:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study to Investigate Contemplative Intervention in Lupus Patients

NCT03103243
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Mindfulness Based Group Sessions
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Jul 22, 2026, 11:18 PM EDT
Completed Phase 4 Interventional

Lupus Atherosclerosis Prevention Study

NCT00120887
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Atorvastatin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2007 · Synced Jul 22, 2026, 11:18 PM EDT
Recruiting Phase 2 Interventional

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07015983
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, Lupus Nephritis
Interventions
CC-97540, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
16 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
40
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 22, 2026, 11:18 PM EDT
Terminated Phase 2 Interventional

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

NCT06161116
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
MK-6194, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Covina, California • La Jolla, California • La Palma, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jul 22, 2026, 11:18 PM EDT
Recruiting Not applicable Interventional

Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus

NCT06232304
View directory record Official record
Conditions
Systemic Lupus Erythematosus of Childhood (Disorder)
Interventions
TEACH
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
12 Years to 22 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Grand Rapids, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jul 22, 2026, 11:18 PM EDT
Completed Phase 2 Interventional Results available

Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

NCT01393132
View directory record Official record
Conditions
Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease
Interventions
Thymosin Beta 4 eye drops, Vehicle Control
Drug
Lead sponsor
Michigan Cornea Consultants, PC
Other
Eligibility
18 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Jul 22, 2026, 11:18 PM EDT
Completed Not applicable Interventional Results available

Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE)

NCT05426902
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
SLE@Duke
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Jul 22, 2026, 11:18 PM EDT
Terminated Not applicable Interventional Results available

Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis

NCT02408471
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus, Osteoarthritis, Post-traumatic Arthritis
Interventions
Ascension® MCP Finger Implant
Device
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
9
States / cities
Tucson, Arizona • Bloomington, Indiana • Carmel, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 22, 2026, 11:18 PM EDT
Recruiting No phase listed Observational

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

NCT05567198
View directory record Official record
Conditions
Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 22, 2026, 11:18 PM EDT